A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 6, 2005, Pages 914-920

  Krishnan, Suganthini ^a   Manavathu, Elias K ^a   Chandrasekar, Pranatharthi H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspergillus fumigatus; Fungal hyphae; Fungicidal activity; Kill curve; Viability test; Voriconazole

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMPHOTERICIN B; GLUCOSE; PEPTONE; VORICONAZOLE;

ARTICLE; ASPERGILLUS FUMIGATUS; CELL VIABILITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; FUNGAL CELL; FUNGICIDAL ACTIVITY; FUNGUS HYPHAE; IN VITRO STUDY; INCUBATION TIME; MYCELIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; TEMPERATURE MEASUREMENT;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPHAE; PYRIMIDINES; TRIAZOLES;

EID: 21244451544     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki100     Document Type: Article

References (37)

1. Brummer E, Kamei K, Miyaji M. Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: a culture and microscopic study. Med Mycol 1998; 36: 227-33.
2. Uzun O, Arikan S, Kocagoz S et al. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn Microbiol Infect Dis 2000; 38: 101-7.
3. Hazen K C, Baron E J, Colombo A L et al. Global Antifungal Surveillance Group. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 2003; 41: 5623-32.
4. Pfaller M A, Messer S A, Boyken L et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201-5.
5. Donnelly J P, De Pauw B E. Voriconazole - a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004; 10: Suppl. 1, 107-17.
6. Hegener P, Troke P F, Fatkenheuer G et al. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12: 2227-8.
7. Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-54.
8. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
9. Li R K, Ciblak M A, Nordoff N et al. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000; 44: 1734-6.
10. Oakley K L, Moore C B, Denning D W. In-vitro activity of vonconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 1998; 42: 91-4.
11. Verweij P E, Mensink M, Rijs A J et al. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 1998; 42: 389-92.
12. Cuenca-Estrella M, Rodriguez-Tudela J L, Mellado E et al. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531-3.
13. Johnson E M, Szekely A, Warnock D W. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42: 741-5.
14. Marco F, Pfaller M A, Messer S A et al. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 1998; 36: 433-6.
15. McGinnis M R, Pasarell L, Sutton D A et al. In vitro activity of voriconazole against selected fungi. Med Mycol 1998; 36: 239-42.
16. Abraham O C, Manavathu E K, Cutright J L et al. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn Microbiol Infect Dis 1999; 33: 7-11.
17. Pfaller M A, Messer S A, Hollis R J et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2000; 46: 1032-7.
18. George D, Miniter P, Andriole V T. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996; 40: 86-91.
19. Murphy M, Bernard E M, Ishimaru T et al. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 696-8.
20. Chandrasekar P H, Cutright J, Manavathu E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother 2000; 45: 673-6.
21. Kirkpatrick W R, McAtee R K, Fothergill A W et al. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 2865-8.
22. Perfect J R, Marr K A, Walsh T J et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
23. Nulens E, Eggink C, Rijs A J et al. Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol 2003; 41: 2261-4.
24. Lai T F, Malhotra. R, Esmail-Zaden R et al. Use of voriconazole in Scedosporium apiospermum keratitis. Cornea 2003; 22: 391-2.
25. Fortun J, Martin-Davila P, Sanchez M A et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22: 408-13.
26. Consigny S, Dhedin N, Datry A et al. Successful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin Infect Dis 2003; 37: 311-3.
27. Stratov I, Korman T M, Johnson P D. Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review. Eur J Clin Microbiol Infect Dis 2003; 22: 277-83.
28. De Lastours V, Lefort A, Zappa M et al. Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis 2003; 22: 297-9.
29. U.S. Food and Drug Administration Approvals, New antimicrobial agents approved by the U.S. Food and Drug Administration in 2003 and new indications for previously approved agents. Antimicrob Agents Chemother 2004; 48: 1438-9.
30. Manavathu E K, Cutright J L, Chandrasekar P H. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-21.
31. Manavathu E K, Cutright J, Chandrasekar P H. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents. J Clin Microbiol 1999; 37: 858-61.
32. Manavathu E K, Cutright J L, Loebenberg D et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46: 229-34.
33. Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 2001; 45: 605-7.
34. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-8.
35. Espinel-Ingroff A, Chaturvedi V, Fothergill A et al. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3776-81.
36. Meletiadis J, Meis J F, Mouton J W et al. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 2000; 38: 2949-54.
37. Manavathu E K, Alangaden G J, Chandraselkar P H. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003; 51: 1423-5.